Journal Article Ppublish 2 citations
PubMed: 38828226 DOI: 10.4081/btvb.2024.120
Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis.
Bleeding Thromb Vasc Biol 3(Suppl 1)
Authors: Maria J Fernandez Turizo, Rushad Patell, Jeffrey I Zwicker
Affiliations
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
- Division of Medical Oncology and Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
- Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
- Weil Cornell Medical College, New York, NY, United States.
Abstract
Comprehensive protein analyses of plasma are made possible by high-throughput proteomic screens, which may help find new therapeutic targets and diagnostic biomarkers. Patients with cancer are frequently affected by venous thromboembolism (VTE). The limited predictive accuracy of current VTE risk assessment tools highlights the need for new, more targeted biomarkers. Although coagulation biomarkers for the diagnosis, prognosis, and treatment of VTE have been investigated, none of them have the necessary clinical validation or diagnostic accuracy. Proteomics holds the potential to uncover new biomarkers and thrombotic pathways that impact the risk of thrombosis. This review explores the fundamental methods used in proteomics and focuses on particular biomarkers found in VTE and cancer-associated thrombosis.
MeSH
Biomarkers, Therapeutics, Thrombosis, Neoplasms, Proteomics